{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:46:23Z","timestamp":1761540383471},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thirty-nine hemophiliac patients, negative for human immunodeficiency virus, with chronic hepatitis C who failed to respond to interferon (IFN) at 3 million units (MU) given subcutaneously thrice weekly for at least 3 months were retreated with 5 MU IFN for 6 months followed by 3 MU IFN in combination with daily oral doses of 1 or 1.2 g ribavirin. Thirty-four patients (87%) completed the study. In 4 patients treatment was discontinued because of treatment-related symptoms; 1 patient dropped out. Dosage reduction was required in 10 patients (26%) because of ribavirin-related anemia or IFN-related side effects. By intention-to-treat analysis, 14 (37%) had a sustained virologic response with preference for those infected by genotypes other than type 1 (43% versus 12%) and with high transaminases levels (168 U\/L versus 116 U\/L). Thus, IFN and ribavirin combination therapy led to a sustained suppression of hepatitis in one third of hemophiliac patients resistant to conventional monotherapy.<\/jats:p>","DOI":"10.1182\/blood.v99.3.1089","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T08:46:40Z","timestamp":1027759600000},"page":"1089-1091","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy"],"prefix":"10.1182","volume":"99","author":[{"given":"Elena","family":"Santagostino","sequence":"first","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Rumi","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Rivi","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[{"name":"From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021216265307900_B1","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)05413-5","article-title":"Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C.","volume":"350","author":"Darby","year":"1997","journal-title":"Lancet."},{"key":"2020021216265307900_B2","first-page":"746","article-title":"The natural history of chronic hepatitis C in hemophiliacs.","volume":"94","author":"Makris","year":"1996","journal-title":"Blood."},{"key":"2020021216265307900_B3","first-page":"3529","article-title":"A multicenter controlled, randomized, open trial of interferon \u03b12b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C.","volume":"89","author":"Rumi","year":"1997","journal-title":"Blood."},{"key":"2020021216265307900_B4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2516.1995.tb00040.x","article-title":"Alpha interferon for hepatitis C virus infection in haemophilic patients.","volume":"1","author":"Telfer","year":"1995","journal-title":"Haemophilia."},{"key":"2020021216265307900_B5","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V87.5.1704.1704","article-title":"Interferon treatment for chronic hepatitis C infections in hemophiliacs. Influence of virus load genotype and liver pathology on response.","volume":"87","author":"Hanley","year":"1996","journal-title":"Blood."},{"key":"2020021216265307900_B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/174.1.1","article-title":"Factors affecting treatment responses to interferon \u03b1 in chronic hepatitis C.","volume":"174","author":"Pawlotsky","year":"1996","journal-title":"J Infect Dis."},{"key":"2020021216265307900_B7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021216265307900_B8","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet."},{"key":"2020021216265307900_B9","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/JVI.71.11.8416-8428.1997","article-title":"Biochemical properties of hepatitis C NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity.","volume":"71","author":"Lohmann","year":"1997","journal-title":"J Virol."},{"key":"2020021216265307900_B10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat Med."},{"key":"2020021216265307900_B11","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: direct molecular test by using ribavirin.","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021216265307900_B12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/0022-1317-79-10-2381","article-title":"The antiviral compound ribavirin modulates the T helper (Th) 1\/Th2 subset balance in hepatitis B and C virus-specific immune responses.","volume":"79","author":"Hultgren","year":"1998","journal-title":"J Gen Virol."},{"key":"2020021216265307900_B13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0016-5085(00)70217-4","article-title":"Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.","volume":"118","author":"Cramp","year":"2000","journal-title":"Gastroenterology."},{"key":"2020021216265307900_B14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/jhep.2001.22346","article-title":"Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.","volume":"33","author":"Di Bisceglie","year":"2001","journal-title":"Hepatology."},{"key":"2020021216265307900_B15","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/JCM.34.4.901-907.1996","article-title":"Accurate quantification of HCV-RNA from all HCV genotypes using branched-DNA (bDNA) technology.","volume":"34","author":"Detmer","year":"1996","journal-title":"J Clin Microbiol."},{"key":"2020021216265307900_B16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2893.1995.tb00009.x","article-title":"Long-term titrated recombinant interferon-\u03b1 2a in chronic hepatitis C: a randomized controlled trial.","volume":"2","author":"Rumi","year":"1995","journal-title":"J Viral Hepat."},{"key":"2020021216265307900_B17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021216265307900_B18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/jhep.2001.20675","article-title":"Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.","volume":"33","author":"Cheng","year":"2001","journal-title":"Hepatology."},{"key":"2020021216265307900_B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jhep.2001.25636","article-title":"A randomized 4-arm multicenter study of interferon \u03b1-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.","volume":"34","author":"Saracco","year":"2001","journal-title":"Hepatology."},{"key":"2020021216265307900_B20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.510260721","article-title":"Factors predictive of a beneficial response to therapy of hepatitis C.","volume":"26(suppl 1)","author":"Davis","year":"1997","journal-title":"Hepatology."},{"key":"2020021216265307900_B21","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.510240609","article-title":"A prospective randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.","volume":"24","author":"Rumi","year":"1996","journal-title":"Hepatology."},{"key":"2020021216265307900_B22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood.V81.2.412.412","article-title":"A multicenter study of viral hepatitis in a United States hemophilic population.","volume":"81","author":"Troisi","year":"1993","journal-title":"Blood."},{"key":"2020021216265307900_B23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V91.2.727","article-title":"High-dose and long-term treatment of \u03b1 interferon in hemophilic patients with chronic C virus hepatitis.","volume":"91","author":"Pinilla","year":"1998","journal-title":"Blood."},{"key":"2020021216265307900_B24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.510270132","article-title":"Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.","volume":"27","author":"Foster","year":"1998","journal-title":"Hepatology."},{"key":"2020021216265307900_B25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","article-title":"Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy.","volume":"29","author":"Bonkovsky","year":"1999","journal-title":"Hepatology."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/3\/1089\/1680647\/1089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/3\/1089\/1680647\/1089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T16:27:03Z","timestamp":1581524823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/3\/1089\/53532\/Sustained-suppression-of-hepatitis-C-virus-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.3.1089","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2,1]]}}}